作者
Keunchil Park, Eric B Haura, Natasha B Leighl, Paul Mitchell, Catherine A Shu, Nicolas Girard, Santiago Viteri, Ji-Youn Han, Sang-We Kim, Chee Khoon Lee, Joshua K Sabari, Alexander I Spira, Tsung-Ying Yang, Dong-Wan Kim, Ki Hyeong Lee, Rachel E Sanborn, José Trigo, Koichi Goto, Jong-Seok Lee, James Chih-Hsin Yang, Ramaswamy Govindan, Joshua M Bauml, Pilar Garrido, Matthew G Krebs, Karen L Reckamp, John Xie, Joshua C Curtin, Nahor Haddish-Berhane, Amy Roshak, Dawn Millington, Patricia Lorenzini, Meena Thayu, Roland E Knoblauch, Byoung Chul Cho
发表日期
2021/10/20
期刊
Journal of Clinical Oncology
卷号
39
期号
30
页码范围
3391-3402
出版商
Wolters Kluwer Health
简介
PURPOSE
Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody with immune cell–directing activity, binds to each receptor's extracellular domain, bypassing resistance at the tyrosine kinase inhibitor binding site.
METHODS
CHRYSALIS is a phase I, open-label, dose-escalation, and dose-expansion study, which included a population with EGFR Exon20ins NSCLC. The primary end points were dose-limiting toxicity and overall response rate. We report findings from the postplatinum EGFR Exon20ins NSCLC population treated at the recommended phase II dose of 1,050 mg amivantamab (1,400 mg, ≥ 80 kg) given once weekly for the first 4 weeks and then once every 2 weeks starting at week 5.
RESULTS
In the efficacy population …
学术搜索中的文章
K Park, EB Haura, NB Leighl, P Mitchell, CA Shu… - Journal of Clinical Oncology, 2021